Text Size

Effects of Age on Response to the 2009 H1N1 Virus Vaccine

This study has been completed.
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by:
University of Rochester
ClinicalTrials.gov Identifier:
NCT01055184
First received: January 5, 2010
Last updated: August 2, 2011
Last verified: October 2010
History of Changes
  Purpose

Unlike most influenza viruses, the 2009 H1N1 virus has affected people between 5 and 40 years old more often than people 60 years old or older. It may be that older people have had greater exposure to previous strains of H1N1 influenza, and this previous exposure protects them from infection. This study will examine how older people respond to a version of the H1N1 virus vaccine that includes a live, noninfectious version of the virus.


Condition Intervention Phase
2009 H1N1 Influenza Virus
 Biological: 2009 H1N1 Virus Vaccine
 Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Assessment of the Effect of Age on the Immunological and Virological Response to a Live Attenuated Influenza Vaccine for the 2009 H1N1 Virus

Resource links provided by NLM:

MedlinePlus related topics: Flu
U.S. FDA Resources

Further study details as provided by University of Rochester:

Primary Outcome Measures:
  • Vaccine virus replication, defined as recovery of vaccine virus in cell culture on 1 or more days [ Time Frame: Measured on Days 2, 5, and 7 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Area under the curve (AUC) of live vaccine virus shedding, calculated by determination of 50% tissue culture infectious dose (TCID50) on Madin Darby canine kidney (MDCK) cells at 33ºC [ Time Frame: Measured at baseline and Day 28 ] [ Designated as safety issue: No ]
  • AUC of vaccine virus copy number assessed by quantitative polymerase chain reaction (PCR) [ Time Frame: Measured at baseline and on Day 28 ] [ Designated as safety issue: No ]
  • Frequency and magnitude of serum hemagglutination inhibition (HAI), enzyme-linked immunosorbent assay (ELISA) and neutralizing antibody response to vaccine [ Time Frame: Measured at baseline and Day 28 ] [ Designated as safety issue: No ]
  • Frequency and magnitude of hemagglutinin-specific mucosal immunoglobulin A (IgA) response, assessed by ELISA on nasal secretions [ Time Frame: Measured at baseline and Day 28 ] [ Designated as safety issue: No ]
  • Frequency of specific local and systemic symptoms occurring after vaccine [ Time Frame: Measured until Day 180 ] [ Designated as safety issue: Yes ]
  • Development of antigen-specific T and B cells following vaccination as assessed by enzyme-linked immunosorbent spot (ELISPOT) assay [ Time Frame: Measured at baseline and on Days 7 and 28 ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: March 2010
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 2009 H1N1 Vaccine
Participants will be stratified by age into two groups: those between 60 and 70 years old, and those older than 70 years of age. All participants will receive the 2009 H1N1 vaccine.
 Biological: 2009 H1N1 Virus Vaccine
Single 0.2 mL dose of live monovalent vaccine, delivered through nasal spray
Other Name: Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal

Detailed Description:

Unlike most influenza viruses, the 2009 H1N1 virus affects many individuals between 5 and 40 years old, but very few 60 years old or older. It is not completely understood why, but scientists believe it may be because older people may have been exposed to other H1N1 viruses in their lives. H1N1 viruses were common until 1957, when they were eclipsed by H2N2 viruses.

In order to test susceptibility to the 2009 H1N1 virus, this study will examine how often people older than 60 get infected by the 2009 H1N1 live attenuated influenza vaccine (LAIV). The LAIV is made from a live virus that has been weakened, so the ability of the immune system to combat this weakened form is likely to mimic its ability to combat the normal form. Additionally, this study will examine how LAIVs work in older people; inactivated virus vaccines are used more often than LAIVs in older people, so little is known of LAIV's effects on this population.

Participation in this study will last 6 months. Participants will be people older than 60, divided into equal groups of people between the ages of 60 and 70 and people older than 70. Both groups will receive one dose of LAIV for 2009 H1N1 vaccine.

There will be six study visits, occurring at baseline and 2, 5, 7, 28, and 180 days after vaccination. Nasal wicks and throat swabs will be taken on Days 2, 5, and 7; a nasal wick alone will be taken at baseline and on Day 28. Blood samples will be taken at baseline and on Days 7 and 28. Participants will undergo physical exams at each visit.

  Eligibility

Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • No prior history of infection with novel H1N1 virus or immunization with novel H1N1 vaccine documented by a laboratory
  • Female participants must not be capable of becoming pregnant or take steps to prevent pregnancy from 30 days before enrollment to 30 days after receiving the study vaccine
  • In good health, as determined by medical history and targeted physical examination
  • Able to understand and comply with the planned study procedures, including being available for all study visits

Exclusion Criteria:

  • Pregnancy
  • Previous history of vaccination against novel H1N1 virus or a laboratory documented history of previous novel H1N1 infection
  • Immunosuppressed as a result of an underlying illness or treatment with immunosuppressive or cytotoxic drugs or use of anticancer chemotherapy or radiation therapy within the preceding 36 months
  • Active neoplastic disease (excluding nonmelanoma skin cancer or prostate cancer that is stable in the absence of therapy) or a history of any hematological malignancy. For this criterion, "active" is defined as having received treatment within the past 5 years.
  • Long-term (greater than 2 weeks) use of oral or parenteral steroids or high-dose inhaled steroids (greater than 800 mcg/day of beclomethasone dipropionate or equivalent) within the 6 months prior to study enrollment (nasal and topical steroids are allowed)
  • Received immunoglobulin or another blood product within the 3 months prior to enrollment in this study
  • Received an inactivated vaccine within 2 weeks or a live vaccine within 4 weeks prior to enrollment in this study or plans to receive another vaccine within the next 28 days
  • Has an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of responses.
  • Has had an acute illness or an oral temperature greater than 99.9°F (37.7°C) within 3 days prior to enrollment or vaccination. Subjects who had an acute illness that was treated with symptoms resolved are eligible to enroll as long as treatment is completed and symptoms are resolved more than 3 days prior to enrollment.
  • Currently participating or plans to participate in a study that involves an experimental agent (vaccine, drug, biologic, device, blood product, or medication), has received an experimental agent within 1 month prior to enrollment in this study, expects to receive another experimental agent during participation in this study, or intends to donate blood during the study period
  • History of alcohol or drug abuse in the 5 years prior to enrollment
  • Has a known human immunodeficiency virus (HIV) or hepatitis B or C infection
  • Has a previous history of Guillain-Barré syndrome
  • Allergic to eggs or egg proteins, gentamicin, gelatin, or arginine or has experienced life-threatening reactions to previous influenza vaccination
  • Has any other condition that would, in the opinion of the site investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01055184

Locations
United States, New York
University of Rochester Medical Center, Vaccine Research Unit
Rochester, New York, United States, 14642
Sponsors and Collaborators
University of Rochester
National Institutes of Health (NIH)
Investigators
Principal Investigator: John Treanor, MD University of Rochester
  More Information

Publications:

Responsible Party: John J. Treanor, MD, Department of Internal Medicine, Division of Infectious Diseases, University of Rochester Medical Center
ClinicalTrials.gov Identifier: NCT01055184     History of Changes
Other Study ID Numbers: URMC 09-009
Study First Received: January 5, 2010
Last Updated: August 2, 2011
Health Authority: United States: Federal Government

Keywords provided by University of Rochester:
Influenza
H1N1

Additional relevant MeSH terms:
Influenza, Human
Virus Diseases
Orthomyxoviridae Infections
 RNA Virus Infections
Respiratory Tract Infections
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 16, 2013